Novavax’s Covid-19 vaccine is 89% effective and works against newer variants of the virus, according to published data from clinical trials in the UK and South Africa.
The US biotech said its trial in partnership with the UK government’s Vaccine Working Group showed 95.6% efficacy against the original strain and 85.6% against B.1.1.7, which was circulating widely in the country during the study.
In a separate Phase 2b study in South Africa, Novavax found that the vaccine was 60% effective in participants without HIV, with none of the cases of Covid-19 in the vaccinated group being severe. The vaccine did not work as well in HIV-positive participants, however, causing the overall efficacy in South Africa to drop to 49%.
Stanley Erck, CEO of Novavax, said it was the “first vaccine to demonstrate not only high clinical efficacy against Covid-19, but also significant clinical efficacy against UK and UK which emerge quickly. South African variants“.
Novavax – which has received up to $ 1.6 billion from Operation Warp Speed, the US government program designed to speed up Covid-19 vaccines – has started its American essay at the end of December.